MedPath

Ibuprofen, Acetaminophen and Dipyrone to Fever Control in Children

Phase 4
Completed
Conditions
Fever
Interventions
Registration Number
NCT01359020
Lead Sponsor
Mantecorp Industria Quimica e Farmaceutica Ltd.
Brief Summary

The purpose of this study was to compare the efficacy and tolerability of acetaminophen, dipyrone and ibuprofen to fever control in children.

For the efficacy asses were compared:

* the time to start the action;

* the action duration;

* the difference between the basal temperature and the lower temperature in the study period.

For the tolerability asses all adverse events were recorded, as well as your intensity and the relation to the treatment.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
396
Inclusion Criteria
  • male and female children aged 06 months to 06 years old, weight above 5 kilo and axillary temperature above 37,5 celsius degree.
Exclusion Criteria
  • patients with a bad general heath state
  • patients with neoplasia, pepic ulcer, gastrointestinal bleeding,history of fever convulsion;
  • intolerant to dypirone, ibuprofen, acetaminophen or any other nonsteroidal antiinflammatory drug;
  • moderated or severe dehydration;
  • conscience state alteration;
  • not capable of ingest oral drugs;
  • patients being treated with steroids;
  • patients treated with antiinflammatory, analgesic and antipyretic drugs in the last 06 hours before the study.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Ibuprofenibuprofen, dipyrone, acetaminophen10 milligram per kilo, oral administration
Acetaminophenibuprofen, dipyrone, acetaminophen10 milligram per kilo, oral administration
Dipyroneibuprofen, dipyrone, acetaminophen10 milligram per kilo, oral administration
Primary Outcome Measures
NameTimeMethod
Antipyretic efficacyTemperature was verified 15, 30, 45 and 60 minutes, 2, 3, 4, 5, 6, 7 and 8 hours after the administration of the drug.

The antipyretic efficacy was assessed comparing the time to the beggining of the action of the drugs, the difference between the final and inicial temperature and time of action.

Secondary Outcome Measures
NameTimeMethod
Adverse EventsAdverse Events were verified at 15, 30, 45 and 60 minutes, 2, 3, 4, 5, 6, 7 and 8 hours after the administration of the drug.

All adverse events were recorded.

Trial Locations

Locations (1)

Instituto de Medicina Integral Professor Fernando Figueira

🇧🇷

Recife, Pernambuco, Brazil

© Copyright 2025. All Rights Reserved by MedPath